Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CLS-AX (axitinib injectable suspension) is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma. It is under Phase 2b clinical trial for the treatment of wet AMD.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Under the agreement, BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME).
Lead Product(s): Avoralstat
Therapeutic Area: Ophthalmology Product Name: BCX4161
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioCryst Pharmaceuticals
Deal Size: $82.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement November 06, 2023
Details:
Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Xipere
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently investigate for neovascular age-related macular degeneration.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
Arcatus is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis and is referred as Xipere, approved in United States.
Lead Product(s): Triamcinolone Acetonide
Therapeutic Area: Ophthalmology Product Name: Arcatus
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Arctic Vision
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently investigate for neovascular age-related macular degeneration.
Lead Product(s): Axitinib,Aflibercept
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
CLS-AX (axitinib) is a tyrosine kinase inhibitor currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. It is being investigated for the treatment if wet AMD.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
CLS-AX (axitinib) is a tyrosine kinase inhibitor currently approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. It is being developed for retinal diseases.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
CLS-AX (axitinib) is a tyrosine kinase inhibitor approved to treat renal cell cancer that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. It is being developed as a long-acting therapy for retinal diseases.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
CLS-AX (axitinib injectable suspension) is proprietary suspension of axitinib tyrosine kinase inhibitor for suprachoroidal injection approved to treat renal cell cancer that achieves pan-VEGF blockade, inhibit VEGF receptors-1, -2, and -3 with high potency and specificity.
Lead Product(s): Axitinib
Therapeutic Area: Ophthalmology Product Name: CLS-AX
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2022